DIRS.INFO The most relevant business & tech news

☆ Stocks making the biggest moves midday: SoFi, ON Semiconductor, Disney, Sweetgreen and more
▼ + stars: | 2023-07-31 | by ( Alex Harring | ) www.cnbc.com time to read: +4 min

SoFi Technologies – Shares of the fintech company popped more than 18% after it reported second-quarter results and lifted its full-year guidance. ON Semiconductor — The chipmaker's shares jumped 3.2% after it posted an earnings and revenue beat for the second quarter. New Relic — Shares jumped 13.4% after a private equity consortium announced it would take the software company private. Sweetgreen — The salad chain's shares jumped 11% Monday after an upgrade from Piper Sandler. Adobe — The software stock jumped 3.9% after Morgan Stanley upgraded the shares to overweight from equal weight.

Persons: FactSet, Disney, Kevin Mayer, Tom Staggs, Bob Iger, Spero, Sweetgreen, Piper Sandler, XPeng, Cowen, Morgan Stanley, Morgan Stanley's, Goldman Sachs, Wayfair, Salesforce's, — CNBC's Hakyung Kim, Yun Li, Sarah Min, Tanaya Macheel, Samantha Subin Organizations: SoFi Technologies, Disney, Financial Times, Food and Drug Administration, UBS, Hasbro, of, Bank of America, CVS, Adobe, Chevron, New York Community Bancorp, Deutsche Bank, CSX, RBC Locations: Bob Iger .

☆ This little-known pharma stock can rally 50%, Citi says
▼ + stars: | 2023-07-31 | by ( Brian Evans | ) www.cnbc.com time to read: +1 min

It's time to buy shares of Ionis Pharmaceuticals , according to Citi. The firm upgraded the stock on Monday to buy from neutral and raised its price target to $60 from $36. "Though HAE is a competitive market, Phase II data hints that it could have an attractive product profile and be a meaningful player," Lebowitz said. Given current valuation, we view the risk-reward on Ionis shares as being skewed positive." Lebowitz also highlighted donidalorsen's phase 2 test performance, which underpinned the stock upgrade.

Persons: David Lebowitz, eplontersen, HAE, Lebowitz, donidalorsen, Ionis, Michael Bloom Organizations: Ionis Pharmaceuticals, Citi, AstraZeneca, donidalorsen, Ionis

☆ On tap this week: Jobs report plus 10 key earnings. Here's what we want to see
▼ + stars: | 2023-07-29 | by ( Zev Fima | ) www.cnbc.com time to read: +18 min

All three major averages advanced for the week, powered by strong mega-cap earnings and favorable inflation data. Looking to next week, earnings season enters its second half with the last of our mega-caps — Apple (AAPL) and Amazon (AMZN) — set to report on Thursday. We'll get a better read on the employment picture on Wednesday with the ADP report and then, more importantly, on Friday's nonfarm payrolls report for July. Thursday after the close brings us to the main events of the week: Earnings from Apple and Amazon. For those looking to review first quarter performance ahead of these releases, be sure to keep our first-quarter earnings report card handy.

Persons: We'll, that's, Stanley Black, Decker, Emerson, Bausch, Leggett, Platt, SIRI, Ares, COLM, PERI, Kraft Heinz, Phillips, Ferrari N.V, Johnson, Robinson, COOK, BUD, Kellogg, Papa, Pitney Bowes, Parker, Trimble, Ziff Davis, Nonfarm, Jim Cramer's, Jim Cramer, Jim, Apple Tim Cook, Kevin Dietsch Organizations: Nasdaq, Dow, Federal Reserve, Federal, ISM Manufacturing, Services PMI, Investors, Caterpillar, Devices, Starbucks, Natural Resources, AMD, Management, Emerson Electric and, Humana, Bausch Health, Apple, Microsoft, Resource Partners, AerCap Holdings, CNA Financial Corp, CNA, Apellis Pharmaceuticals, Bank, SJW, Hutchison China MediTech, Camtek Ltd, Silvercrest Asset Management, Loews Corp, Oxford Lane Capital Corp, Banco Santander, Silicom Ltd, SuperCom Ltd, Arista Networks, Avis Budget Group, Diamondback Energy, Lattice Semiconductor Corp, Republic Services, Yum China Holdings, Western Digital Corp, Power Systems, Tenet Healthcare Corp, Vornado Realty, BioMarin Pharmaceutical, PetMed, SBA Communications Corporation, Brixmor, Snack Foods Corp, Cushman & Wakefield, Sanmina Corporation, TFI, PMI, Cruise Line Holdings Ltd, Uber Technologies, Pfizer, Enterprise Products Partners, Merck, JetBlue Airways Corporation, Allegro MicroSystems, Altria, SunPower Corp, SiriusXM Holdings, Molson Coors Beverage, Marriott International, Toyota Motor Corp, BP, SYSCO Corp, Marathon Petroleum Corp, Ares Management, Equitrans Midstream Corporation, Game Technology, Illinois Tool, IDEXX Laboratories, Rockwell Automation, Packaging International Corp, Gartner, Zebra Technologies Corp, IQVIA Holdings, Oshkosh Corporation, Leidos Holdings, Eaton Corp, yte Corp, Lear Corp, Starbucks Corp, Devon Energy Corp, SolarEdge Technologies, Lumen Technologies, Virgin Galactic Holdings, Caesars Entertainment, VF Corp, Sciences Corp, Paycom, Vertex Pharmaceuticals, Suncor Energy, Holdings, Chesapeake Energy Corp, Boston Properties, American International Group, AIG, Allstate Corp, Aspen Technology, Electronic Arts, EA, Flowserve Corporation, Denny's, Corp, Prudential Financial, Store, Ternium S.A, Vimeo, Emerson, Lomb, CVS Health, Generac Holdings, Cameco Corp, Perion Network Ltd, Builders, Carlyle Group, Scorpio, Teva Pharmaceutical Industries, Ltd, Rithm Capital Corp, AeroSystems Holdings, Vertiv Holdings Co, Johnson Controls, CDW Corp, DuPont, Brands Holdings, Scotts Miracle, Gro, SMG, Brands, Allegheny Technologies, AmerisourceBergen Corporation, ABC, Real Estate Corporation, Adient plc, Editas, Garmin Ltd, WWE, Bunge Ltd, Criteo S.A, PayPal, QUALCOMM, Occidental Petroleum Corp, Apache Corp, Albemarle Corp, MGM Resorts International, MGM, Marathon Oil Corp, Joby Aviation, Industrial, CF Industries Holdings, Goodyear Tire &, Realty ome Corp, Metlife, Pacific Biosciences of, Rush Street Interactive, Zillow, JFrog Ltd, Herbalife Nutrition Ltd, Simon Property Group, McKesson Corp, Storage, Cerus Corporation, GXO Logistics, MAX Holdings, Health, Anheuser, Busch InBev, Warner Bros ., Cheniere Energy, ConocoPhillips, Hasbro, CIGNA Corp, Lantheus Holdings, Regeneron Pharmaceuticals, Fiverr International, Air Products & Chemicals, TopBuild Corp, EPAM Systems, Lightspeed Commerce, Aurinia Pharmaceuticals, Cummins, CMI, Slair Corporation, Starwood Property Trust, Vulcan, Alnylam Pharmaceuticals, New Energy Corp, Cedar Fair Entertainment, Intellia Therapeutics, Lending, Privia Health, Dickinson, Chimera Investment, CIM, Hyatt Hotels Corp, Lion Electric, LEV, Deluxe Corp, Murphy Oil Corp, PBF Energy, Papa John's, Targa Resources Corp, Wix.com Ltd, Apollo Global Management, LLC, Butterfly, Sempra Energy, Aptiv PLC, Brookfield Infrastructure Partners, Canada Goose Holdings, Hannifin Corporation, WESCO International, WCC, Arrow Electronics, Constellation Energy Group, Midstream Partners, Coinbase, Petroleo Brasileiro SA Petrobras, Gilead Sciences, Opendoor Technologies, Booking Holdings, Atlassian Corporation, International, Redfin Corporation, Motorola Solutions, Monster Beverage Corporation, Consolidated Edison, Rocket Companies, Apple Hospitality, Cirrus, Resources, Universal Display Corporation, Chesapeake Utilities Corp, Social, Defense, Security Solutions, Post Holdings, Tandem Diabetes Care, Nikola Corporation, Magna International, Dominion Energy, ACM Research, Frontier Communications, Brookfield Renewable Partners, inTEST Corporation, American Pipeline, TELUS International, XPO Logistics, Fluor Corp, Gray Television, Cboe, LyondellBasell Industries, Twist Bioscience, Global, Jim Cramer's Charitable, CNBC, Allen & Company Sun Valley, Getty Locations: U.S, China, India, Oxford, Chile, Illinois, Columbia, Pacific, Pacific Biosciences of California, Southern, PBI, Gilead, Sun Valley , Idaho

☆ Focus: Drugmakers go under the skin, skirting early US Medicare price negotiations
▼ + stars: | 2023-07-28 | by ( Michael Erman | ) www.reuters.com time to read: +5 min

Each year, Medicare will add more drugs to the list, the names of which have not yet been disclosed. Faspro, launched in 2020, already accounts for more than 80% of Darzalex revenue, which is due to rise to $9.5 billion this year. Merck previously told Reuters it expects this version of Keytruda could replace the more time consuming infusion for most patients. Keytruda revenue is expected to top $24 billion this year and could exceed $30 billion as soon as 2026, according to analyst estimates. The company has said its expects revenue from subcutaneous drugs containing hyaluronidase to drive its growth going forward.

Persons: Srdjan, Johnson, drugmakers, Bristol Myers, Roche, Biden’s, Michael DiFiore, DiFiore, Joseph Wolk, Faspro, Halozyme, Helen Torley, hyaluronidase, Michael Erman, Patrick Wingrove, Caroline Humer, Bill Berkrot Organizations: U.S, REUTERS, Wall Street, Merck & Co, Halozyme Therapeutics, Reuters, Bristol, Bristol Myers Squibb, Medicare, U.S . Centers, Medicaid Services, J, Reuters Graphics Merck, Merck, Thomson Locations: Ljubljana, Darzalex, Diego

☆ U.S. FDA approves second over-the-counter opioid overdose reversal drug
▼ + stars: | 2023-07-28 | by ( ) www.cnbc.com time to read: +1 min

Naloxone, packaged with instructions, is one of the items given out by the Baltimore Harm Reduction Coalition outreach workers. The U.S. Food and Drug Administration has approved the prescription-free sale of the second opioid overdose reversal drug, its manufacturer Harm Reduction Therapeutics said on Friday. The approval of the drug, called RiVive, will provide patients with another over-the-counter option in the United States, where drug-related overdose deaths surpassed 100,000 in 2021. Harm Reduction said it anticipates that RiVive will be available early next year, primarily to harm-reduction organizations and state governments. Harm Reduction Therapeutics has partnered with contract drug manufacturer Catalent Inc to manufacture RiVive.

Persons: drugmaker, Michael Hufford, BioSolutions Organizations: Reduction Coalition, U.S . Food, Drug Administration, Therapeutics, Harm, Catalent Inc Locations: Baltimore, U.S, United States

☆ US FDA approves second over-the-counter opioid overdose reversal drug
▼ + stars: | 2023-07-28 | by ( ) www.reuters.com time to read: +1 min

July 28 (Reuters) - The U.S. Food and Drug Administration has approved the prescription-free sale of the second opioid overdose reversal drug, its manufacturer Harm Reduction Therapeutics said on Friday. The approval of the drug, called RiVive, will provide patients with another over-the-counter option in the United States, where drug-related overdose deaths surpassed 100,000 in 2021. Harm Reduction said it anticipates that RiVive will be available early next year, primarily to harm-reduction organizations and state governments. Harm Reduction Therapeutics has partnered with contract drug manufacturer Catalent Inc (CTLT.N) to manufacture RiVive. Reporting by Sriparna Roy and Bhanvi Satija in Bengaluru; Editing by Pooja DesaiOur Standards: The Thomson Reuters Trust Principles.

Persons: drugmaker, Michael Hufford, Sriparna Roy, Bhanvi, Pooja Desai Organizations: U.S . Food, Drug Administration, Therapeutics, Harm, Catalent Inc, Thomson Locations: U.S, United States, Bengaluru

Investors upped their short bets on a handful of clean energy and biotechnology stocks during the first half of July, according to FactSet data. Allogene Therapeutics held the greatest short interest of the group, at about 54% of float, with Novavax and ProKidney Corp. also appearing on the list. Short interest declined slightly in ProKidney shares. Short interest in shares declined 8.6% during the first half of July, although about 35% of its shares are sold short. saw short interest leap 10% since the end of June.

Persons: BioXcel Organizations: BioXcel Therapeutics, Allogene Therapeutics, ProKidney Corp, Research, CNBC Pro, New York Stock Exchange, Nasdaq

☆ Japan's Takeda beats Q1 profit estimates on mainstay drugs, dengue vaccine
▼ + stars: | 2023-07-27 | by ( ) www.reuters.com time to read: +2 min

Companies Takeda Pharmaceutical Co Ltd FollowTOKYO, July 27 (Reuters) - Japan's Takeda Pharmaceutical (4502.T) posted first-quarter profit that beat analysts' estimates, citing solid sales of mainstay drugs and the launch of new products including its dengue fever vaccine. Operating profit rose 12% from a year earlier to 168.6 billion yen ($1.2 billion) in the three months through June 30, the drugmaker said. That compared with an average forecast of 150.7 billion yen from six analysts polled by Refinitiv. The company held its forecast for full-year operating profit at 349 billion yen. Analysts expect 481.1 billion yen on average for the year.

Persons: Takeda, Rocky Swift, Tom Hogue, Robert Birsel Organizations: Takeda Pharmaceutical, Refinitiv, Therapeutics, Shire Plc, Nikkei, Thomson Locations: Japan, United States, U.S

☆ This under-the-radar biotech could be the next way to play the obesity drug boom
▼ + stars: | 2023-07-27 | by ( Christina Cheddar Berk | ) www.cnbc.com time to read: +3 min

"With 8 direct and 15 indirect catalysts in the next ~12-18 months, we see several near-term opportunities to further drive GPCR shares," Rahimi wrote in a research note. Structure's ticker symbol is a nod to the company's research, which focuses on G protein-coupled receptors, or GPCRs, a growing area of drug development. GSBR-1290 is Structure's GLP-1R agonist that is being studied as treatment for type 2 diabetes and obesity. If successful, the drug could one day compete against Novo Nordisk's blockbusters Ozempic and Wegovy and Eli Lilly's Mounjaro. Separately, the analyst said Structure's other early stage drug candidate, LTSE-2578, provides further upside as investors have largely overlooked the opportunity it provides.

Persons: Piper Sandler, Yasmeen, Rahimi, Eli Lilly's Mounjaro, Wegovy Organizations: Therapeutics, Novo, ShouTi Inc, Nasdaq Locations: San Francisco, Shanghai

NEW YORK, July 26 (Reuters) - British billionaire Joe Lewis has surrendered to U.S. authorities in Manhattan and is expected to appear in court later on Wednesday to face insider trading charges, a spokesperson for the U.S. Attorney's office in Manhattan said. Two of Lewis' pilots, Patrick O'Connor and Bryan Waugh, were also charged with insider trading securities fraud. Joe Lewis is a wealthy man," Damian Williams, the U.S. Attorney in Manhattan, said in a statement. Insider trading has long been a focus of Williams' office, dating to 2009 when a crackdown began under one of his predecessors, Preet Bharara. Separately on Wednesday, the U.S. Securities and Exchange Commission filed a civil insider trading case against Lewis, O'Connor, Waugh and Lewis' then-girlfriend Carolyn Carter.

Persons: Joe Lewis, Lewis, Patrick O'Connor, Bryan Waugh, David Zornow, O'Connor, Waugh, O'Connor texted, Mirati, Daniel Levy, Dylan Martinez, Damian Williams, Williams, Preet Bharara, Carolyn Carter, Carter, Gurbir Grewal, Luc Cohen, Jonathan Stempel, Chris Prentice, Chizu Nomiyama, Daniel Wallis Organizations: YORK, U.S, Tottenham Hotspur, Tottenham, Prosecutors, Mirati Therapeutics, Southampton Premier League, Reuters, Tavistock Group, Forbes, Attorney, U.S . Securities, Exchange Commission, SEC, Thomson Locations: British, U.S, Manhattan, United States, New York, Virginia

NEW YORK, July 25 (Reuters) - Joe Lewis, the British billionaire and owner of the Tottenham Hotspur soccer team, has been criminally charged in New York for orchestrating a "brazen" insider trading scheme. Joe Lewis is a wealthy man," U.S. Attorney Damian Williams said in a video on the X social media platform, formerly known as Twitter. Insider trading has long been a focus of Williams' office, dating to 2009 when a crackdown began under one of his predecessors, Preet Bharara. Prosecutors said that in some insider trading cases, Lewis lent money to recipients of his tips, including in Oct. 2019 when he wired $1 million to two pilots so they could buy more Mirati shares. Reporting by Jonathan Stempel and Luc Cohen in New York; Editing by Chris Reese and Lincoln Feast.

Persons: Joe Lewis, Lewis, Damian Williams, " Williams, Williams, Preet Bharara, Mirati, Boss, Marty, JPMorgan Chase, Jonathan Stempel, Luc Cohen, Chris Reese, Lincoln Organizations: YORK, Tottenham Hotspur, Prosecutors, U.S, Tavistock Group, Forbes, Therapeutics, Biosciences, Australian Agricultural, U.S . Securities, Exchange Commission, JPMorgan, Thomson Locations: New York, Tavistock, Bear Stearns

☆ Joe Lewis, Billionaire Owner of Tottenham Hotspur, Charged with Insider Trading
▼ + stars: | 2023-07-26 | by ( Michael J. De La Merced | More About Michael J. De La Merced | ) www.nytimes.com time to read: +1 min

Federal prosecutors charged Joseph C. Lewis, the British billionaire who owns the Tottenham Hotspur English soccer club, with insider trading on Tuesday, accusing him of illegally funneling nonpublic information to associates to trade on. In a 29-page indictment, prosecutors in Manhattan accused the 86-year-old financier of doling out tips to friends and associates, including his pilots, personal assistants and romantic partners from 2019 to 2021. “He used inside information as a way to compensate employees and shower gifts on friends and lovers,” Damian Williams, the United States Attorney for the Southern District of New York, said in a statement. “It’s cheating and against the law.”Prosecutors also accused Mr. Lewis of conspiring to hide a roughly 20 percent stake in Mirati Therapeutics, a pharmaceutical company, through a series of shell companies and false statements to the Securities and Exchange Commission.

Persons: Joseph C, Lewis, ” Damian Williams, “ It’s, ” Prosecutors Organizations: Tottenham Hotspur English, United States, Southern, of, ”, Mirati Therapeutics, Securities and Exchange Commission Locations: Manhattan, of New York

☆ Flipping a Switch and Making Cancers Self-Destruct
▼ + stars: | 2023-07-26 | by ( Gina Kolata | More About Gina Kolata | ) www.nytimes.com time to read: +1 min

Within every cancer are molecules that spur deadly, uncontrollable growth. What if scientists could hook those molecules to others that make cells self-destruct? Could the very drivers of a cancer’s survival instead activate the program for its destruction? “It’s very cool,” said Jason Gestwicki, professor of pharmaceutical chemistry at the University of California, San Francisco. “It turns something the cancer cell needs to stay alive into something that kills it, like changing your vitamin into a poison.”

Persons: Gerald Crabtree, ”, Crabtree, Nathanael S, Gray, “, Jason Gestwicki Organizations: Stanford, redwoods, Foghorn Therapeutics, University of California Locations: Santa Cruz, San Francisco

☆ British billionaire Joe Lewis to appear in U.S. court on insider trading charges
▼ + stars: | 2023-07-26 | by ( ) www.cnbc.com time to read: +2 min

Joe Lewis at a Tottenham vs. Arsenal soccer match in north London in 2011. British billionaire Joe Lewis has surrendered to U.S. authorities in Manhattan and is expected to appear in court later on Wednesday to face insider trading charges, a spokesperson for the U.S. Attorney's office in Manhattan said. Two of Lewis' pilots, Patrick O'Connor and Bryan Waugh, were also charged with insider trading securities fraud. They reaped millions of dollars in illegal profit from Lewis' tips, prosecutors said. After Mirati announced the positive results, its share price increased 16.7% in one day, and both pilots repaid Lewis for his loans.

Persons: Joe Lewis, Lewis, Patrick O'Connor, Bryan Waugh, David Zornow, O'Connor, Waugh, O'Connor texted, Mirati Organizations: Tottenham, Arsenal, U.S, Tottenham Hotspur, Prosecutors, Mirati Therapeutics Locations: London, U.S, Manhattan, United States

Companies Mirati Therapeutics Inc FollowNEW YORK, July 26 (Reuters) - The British billionaire Joe Lewis pleaded not guilty on Wednesday to orchestrating what prosecutors called a "brazen" insider trading scheme by passing tips about companies in which he invested to friends, private pilots and a former girlfriend. Two of Lewis' pilots, Patrick O'Connor and Bryan Waugh, also pleaded not guilty to related insider trading charges, after being accused of making millions of dollars in illegal profit from Lewis' tips. British billionaire and Tottenham Hotspur owner Joe Lewis exits the United States Courthouse in Manhattan, following his appearance on insider trading charges, in New York City, U.S., July 26, 2023. Insider trading has long been a focus of Williams' office, dating to 2009 when a crackdown began under one of his predecessors, Preet Bharara. Separately on Wednesday, the U.S. Securities and Exchange Commission filed a civil insider trading case against Lewis, O'Connor, Waugh and Lewis' former girlfriend Carolyn Carter.

Persons: Joe Lewis, Lewis, Valerie Figueredo, Nicolas Roos, Patrick O'Connor, Bryan Waugh, David Zornow, O'Connor, Waugh, O'Connor texted, Mirati, Amr Alfiky Mirati, Prosecutors, Damian Williams, Williams, Preet Bharara, Carolyn Carter, Carter, Gurbir Grewal, Luc Cohen, Jonathan Stempel, Jody Godoy, Chris Prentice, Chizu Nomiyama, Daniel Wallis Organizations: Mirati Therapeutics, Tottenham Hotspur, Aviva, Tavistock Group, Forbes, Tottenham, Prosecutors, United, REUTERS, U.S, Attorney, U.S . Securities, Exchange Commission, SEC, Thomson Locations: British, Manhattan, United States, New York City, U.S, New York, Virginia, South Korea

☆ Danaher cut its outlook for 2023, but we're maintaining our rating — here's why
▼ + stars: | 2023-07-25 | by ( Zev Fima | ) www.cnbc.com time to read: +9 min

Life sciences and medical diagnostics company Danaher (DHR) delivered a second-quarter earnings beat on Tuesday, but lowered its outlook for the year. When excluding the impact of Covid-related tests and products, Danaher realized base-business core sales growth of 2%. As a result, management was once again forced to downwardly revise their sales growth outlook for the year. We predict a bioprocessing bottom this year, early next year at the very latest, setting us for a rebound in organic revenue growth. This updated outlook represents a downward revision from the high-single-digit percentage decline previously expected on a core basis and the mid-single-digit percentage growth previously expected for the base business.

Persons: Danaher, Cash, Bioprocessing, That's, Sartorius, Cepheid, Jim Cramer's, Jim Cramer, Jim, Marisol Darge, Robert McCabe, Hyoung Chang Organizations: Revenue, Management, Wall, Biotechnology, pharma, CNBC, Kaiser Permanente Arapahoe Medical, Getty Locations: DHR, China, Base, Centennial , Colorado, Denver

☆ Lightning Round: Walk away from AT&T, says Jim Cramer
▼ + stars: | 2023-07-24 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailLightning Round: Walk away from AT&T, says Jim Cramer'Mad Money' host Jim Cramer weighs in on stocks including: Seres Therapeutics, AT&T, Centrus Energy, Genius Sports, Enovix, Verizon and SLB.

Persons: Jim Cramer Organizations: Seres Therapeutics, Centrus Energy, Genius, Verizon

☆ The market is going through a short squeeze of historic proportions, even bigger than the meme craze
▼ + stars: | 2023-07-24 | by ( Yun Li | ) www.cnbc.com time to read: +2 min

Remember the GameStop mania of 2021, fueled as it was by forcing short sellers to cover their bets? However, when the stock jumps instead, it forces short sellers to buy back shares in order to limit their losses. The stock market is in the middle of a strong rally as inflation pressures ease and the Fed nears the end of its rate-hiking campaign. GameStop was once the most shorted stock in the market, with short interest as a percentage of shares available for trading exceeding 100%. Carvana , Novavax, Lucid Group and Beyond Meat were also heavily targeted by short sellers.

Persons: Adam Parker, Trivariate, Parker Organizations: Research, Fed, Dow Jones, GameStop, Nasdaq, Therapeutics

☆ Cramer's Lightning Round: Walk away from AT&T
▼ + stars: | 2023-07-24 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

Stock Chart Icon Stock chart icon Seres Therapeutics' year-to-date stock performance. Stock Chart Icon Stock chart icon AT&T's year-to-date stock performance. Stock Chart Icon Stock chart icon Centrus Energy's year-to-date stock performance. Stock Chart Icon Stock chart icon Enovix's year-to-date stock performance. Stock Chart Icon Stock chart icon Verizon's year-to-date stock performance.

Persons: it's, Centrus, I've, that's, It's Organizations: Therapeutics, Seres Therapeutics, Centrus, Verizon, Mobile, Schlumberger Locations: Southern, Haliburton, SLB

Rare diseases treatment developer Travere Therapeutics has the potential for meaningful long-term value, according to JPMorgan. Analyst Anupam Rama initiated coverage on Travere with an overweight rating Friday. The December 2024 price target of $26 implies shares surging 66% from Thursday's close. Earlier this year, Filspari received accelerated approval from the U.S. Food and Drug Administration. The company is also awaiting regulatory feedback for pegtibatinase , which is designed to treat classical homocystinuria, a rare genetic metabolic disorder.

Persons: Anupam Rama, Filspari, Rama, — CNBC's Michael Bloom Organizations: Travere Therapeutics, JPMorgan, U.S . Food, Drug Administration Locations: Thursday's, U.S

☆ Pfizer says no major tornado damage to drug manufacturing areas of North Carolina facility
▼ + stars: | 2023-07-21 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +2 min

In this aerial image, damage is seen to a Pfizer pharmaceutical factory after a tornado hit the facility two days earlier, on July 21, 2023 in Rocky Mount, North Carolina. Pfize r on Friday said there does not appear to be major damage to the drug manufacturing areas of its plant in Rocky Mount, North Carolina, after a tornado hit the facility two days earlier. The North Carolina plant is closed while Pfizer and both local and federal authorities further evaluate the damage. It's one of 10 Pfizer manufacturing sites in the country. Pfizer also noted that it is working closely with Food and Drug Administration Commissioner Robert Califf, North Carolina Gov.

Persons: it's, Robert Califf, Roy Cooper, Califf Organizations: Pfizer, Food and Drug, North Carolina Gov, FDA Locations: Rocky Mount, North Carolina, U.S, North

☆ Cramer's Lightning Round: KeyCorp is a buy
▼ + stars: | 2023-07-20 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

Stock Chart Icon Stock chart icon Illumina's year-to-date stock portfolio. Stock Chart Icon Stock chart icon Compass Pathways' year-to-date stock performance. Stock Chart Icon Stock chart icon KeyCorp's year-to-date stock performance. Stock Chart Icon Stock chart icon Eaton's year-to-date stock performance. Stock Chart Icon Stock chart icon ASML Holding's year-to-date stock performance.

Persons: Eaton, you've, ASML Organizations: Verve Therapeutics, ASML, Taiwan Semi Locations: Informatica, Taiwan

☆ Pfizer, Flagship Pioneering to invest $100 mln in drug discovery
▼ + stars: | 2023-07-18 | by ( ) www.reuters.com time to read: +2 min

July 18 (Reuters) - U.S. drugmaker Pfizer (PFE.N) and venture firm Flagship Pioneering on Tuesday said they would invest $100 million together to develop up to 10 new potential drugs for areas including internal medicine, oncology, infectious diseases and immunology. Flagship, which has incubated biotech companies, most famously Moderna Inc (MRNA.O), and Pfizer will each invest $50 million. Flagship's drug discovery initiative Pioneering Medicines will lead the exploration process. Paul Biondi, president of Flagship's Pioneering unit and a former top Bristol Myers Squibb (BMY.N) executive, said the partnership will take advantage of Flagship's abilities to develop novel technologies towards bigger disease areas. Drug developers such as Denali Therapeutics (DNLI.O), Foghorn Therapeutics (FHTX.O) and Sana Biotechnology (SANA.O) are some of the other companies backed by Flagship.

Persons: Paul Biondi, Biondi, Mikael Dolsten, Foghorn, Bhanvi, Michael Erman, Shilpi Majumdar, Alexandra Hudson Organizations: drugmaker Pfizer, Moderna Inc, Pfizer, Flagship's, Bristol Myers Squibb, Flagship, Therapeutics, Foghorn Therapeutics, Sana Biotechnology, Alexandra Hudson Our, Thomson Locations: Bengaluru, New Jersey

☆ A serious accident inspired a biomedical engineer to build a VR rehab company. Things really took off when she tapped into 5G speeds.
▼ + stars: | 2023-07-17 | by ( Sarah Sloat | ) www.businessinsider.com time to read: +6 min

She founded Immersive Rehab, a digital-therapeutics company. In September 2016, Van De Keere founded Immersive Rehab, a social-enterprise startup. A Paralympic athlete and spinal-injury patient getting treatment using an Immersive Rehab tool. Immersive Rehab utilizes off-the-shelf technology including VR headsets, laptops, and external motion-tracking sensors. She said she's already seen incredible growth in headset innovation since Immersive Rehab launched.

Persons: Isabel Van De Keere, Isabel Van De, Van De Keere, Van de Keere, They've, she's, It's, we've Organizations: VR Locations: London, United Kingdom, Germany, United States

☆ US FTC seeks additional info on Pfizer's proposed takeover of Seagen
▼ + stars: | 2023-07-15 | by ( ) www.reuters.com time to read: +1 min

[1/2] The Pfizer logo is pictured on their headquarters building in the Manhattan borough of New York City, New York, U.S., November 9, 2020. REUTERS/Carlo Allegri/File Photo/File PhotoJuly 14 (Reuters) - The US Federal Trade Commission (FTC) has sought additional information and documentary material related to Pfizer's (PFE.N) proposed acquisition of Seagen Inc (SGEN.O), Seagen said on Friday. The antitrust agency sent the requests separately to both the companies, a regulatory filing said. Pfizer struck a $43 billion deal in March to acquire Seagen and its targeted cancer therapies, to counter the fall in COVID-related sales and generic competition for some top-selling drugs. The recent scrutiny by the antitrust agency to block Amgen's (AMGN.O) $27.8 billion deal to buy Horizon Therapeutics (HZNP.O) has made investors jittery around the Pfizer-Seagen deal as well.

Persons: Carlo Allegri, Seagen, Khushi, Shailesh Organizations: Pfizer, REUTERS, US Federal Trade Commission, Seagen Inc, Horizon Therapeutics, Thomson Locations: Manhattan, New York City , New York, U.S, COVID, Bengaluru

Search resuls for: "THERAPEUTICS"

25 mentions found